Frontiers in Immunology (Aug 2022)

Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination

  • Marta Sisteré-Oró,
  • Naina Andrade,
  • Diana D.J. Wortmann,
  • Juan Du,
  • Natalia Garcia-Giralt,
  • María González-Cao,
  • Robert Güerri-Fernández,
  • Robert Güerri-Fernández,
  • Robert Güerri-Fernández,
  • Andreas Meyerhans,
  • Andreas Meyerhans

DOI
https://doi.org/10.3389/fimmu.2022.994173
Journal volume & issue
Vol. 13

Abstract

Read online

Individuals infected with the human immunodeficiency virus type 1 (HIV-1) belong to the group of people most vulnerable to SARS-CoV-2 infections and the associated disease COVID-19. Here we describe SARS-CoV-2-specific antibody and cellular immune responses in a small cohort of immunological non-responder HIV-1 patients (HIV-INRs) after receiving the COVID-19 mRNA-based BioNTech/Pfizer vaccine. Compared to the control group of vaccinated healthy individuals that all developed a virus-specific immune response, 5 of 10 vaccinated HIV-1 patients showed insufficient immune responses. The lack of response was not directly correlated with patients CD4 cell counts. Three of the five non-responders that agreed to receive a booster vaccination subsequently generated a virus-specific response. Thus, even HIV-INRs can be efficiently vaccinated against COVID-19 but may require a follow-up by virus-specific immune monitoring to guarantee clinical vaccine benefits.

Keywords